Stocks on Sale: Hershey, Monster, Altria, and Mobileye
Amid stock markets at an all-time high, investors have just a few bargain opportunities today.Hershey (HSY) broke down from an uptrend recently, turning back from $176 to close at $161.95 on July 8. Wendy’s (WEN) announced that its CEO, Kirk Tanner, left the firm to join as Hershey’s CEO. Investors did not react positively yesterday. HSY stock fell by 4.7%.Monster Beverage (MNST) is forming a downtrend after shares failed to break out past $64.45. MSNT stock closed down by 3.28% to close at $59.57. Investors likely took advantage of Stiefel issuing a “buy” rating on the stock. Stiefl is bullish on Monster’s performance in global markets. The firm dismissed higher costs related to aluminum. President Trump slapped a 50% tariff on the raw material.Tobacco firm Altria Group (MO) unexpectedly fell by 3.01% on Wednesday to close at $57.75. Jefferies rated Philip Morris (PM) and Imperial Brands (IMBBY) with a bullish report. But it rated Altria with an underperform rating. It thinks the US Combustibles market has risks. Weakness in Traditional Oral is a headwind, while Modern Oral would grow.Mobileye (MBLY) dropped by 7.08% to close at $17.32. Intel (INTC) plans to sell 45 million MBLY shares. It held 711.5 million Class B shares at the end of the first quarter.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


